Table 1 Patients and tumor characteristics of the h-R3/RT and CDDP/RT groups (N = 104)
h-R3/RT (N = 52) | CDDP/RT (N = 52) | ||
|---|---|---|---|
Characteristics | [n (%)] | [n (%)] | P Value* |
Age | 1.000 | ||
  < 60 | 45 (86.5%) | 45 (86.5%) | |
 ≧60 | 7 (13.5%) | 7 (13.5%) | |
Sex | 0.083 | ||
 Male | 42 (82.7%) | 36 (69.2%) | |
 Female | 10 (17.3%) | 16 (30.8%) | |
T category | 0.799 | ||
 1 | 11 (21.2%) | 11 (21.2%) | |
 2 | 13 (25.0%) | 14 (26.9%) | |
 3 | 12 (23.1%) | 12 (23.1%) | |
 4 | 16 (30.7%) | 15 (28.8%) | |
N category | 0.957 | ||
 0 | 3 (5.8%) | 4 (7.7%) | |
 1 | 20 (38.4%) | 19 (36.5%) | |
 2 | 23 (44.3%) | 23 (44.3%) | |
 3 | 6 (11.5%) | 6 (11.5%) | |
M category | 1.000 | ||
 0 | 52 (100%) | 52 (100%) | |
 1 | 0 (0.00%) | 0 (0.00%) | |
Clinical stage | 0.831 | ||
 II | 13 (25.0%) | 13 (25.0%) | |
 III | 20 (38.5 0%) | 21 (40.4%) | |
 IV (non-metastatic) | 19 (36.5.0%) | 18 (34.6%) | |
Histologic type | |||
 non-keratinizing | 52 (100%) | 52 (100%) | |
 Total RT | (70/74)a | (70/74)a | |
dose (Gy) | |||
 ECOG | 0-2 | 0-2 | |